CTS On The Rebound?
Executive Summary
In the battle for the minimally-invasive cardiac surgery market, CTS has long been seen as second fiddle to HeartPort. But while HeartPort has struggled, CTS has been growing nicely. With nearly 50% of the minimally-invasive cardiac surgery market, CTS is now the market leader and watching competitors fall by the wayside. Now the trick is convincing investors.